0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Circulating Tumor Cell Diagnostics - Global Market Insights and Sales Trends 2024
Published Date: November 2023
|
Report Code: QYRE-Othe-362
Home | Market Reports | Health| Health Conditions| Cancer
Global Circulating Tumor Cell Diagnostics Market Insights and Forecast to 2028
BUY CHAPTERS

Circulating Tumor Cell Diagnostics - Global Market Insights and Sales Trends 2024

Code: QYRE-Othe-362
Report
November 2023
Pages:124
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Circulating Tumor Cell Diagnostics - Market Size

The global Circulating Tumor Cell Diagnostics market size is expected to reach US$ 9239.7 million by 2029, growing at a CAGR of 9.2% from 2023 to 2029.

Circulating Tumor Cell Diagnostics -  Market

Circulating Tumor Cell Diagnostics - Market

Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
The market is mainly driven by the significant applications of Circulating Tumor Cell Diagnostics in various end use industries. The expanding demands from the Tumorigenesis research, EMT biomarkers development, Cancer stem cell research and Others, are propelling Circulating Tumor Cell Diagnostics market. CTC Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTC Detection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cell Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Circulating Tumor Cell Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cell Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cell Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cell Diagnostics covered in this report include Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc. and Fluxion Biosciences Inc., etc.
The global Circulating Tumor Cell Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc

Scope of Circulating Tumor Cell Diagnostics - Market Report

Report Metric Details
Report Name Circulating Tumor Cell Diagnostics - Market
Forecasted market size in 2029 US$ 9239.7 million
CAGR 9.2%
Forecasted years 2023 - 2029
Global Circulating Tumor Cell Diagnostics market, by region:
  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cell Diagnostics market, Segment by Type:
  • CTC Enrichment
  • CTC Detection
  • CTC Analysis
Global Circulating Tumor Cell Diagnostics market, by Application
  • Tumorigenesis research
  • EMT biomarkers development
  • Cancer stem cell research
  • Others
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter Four: Detailed analysis of Circulating Tumor Cell Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
  • Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
  • Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What is the Circulating Tumor Cell Diagnostics - Market size in 2029?

Ans: The Circulating Tumor Cell Diagnostics - Market size in 2029 will be US$ 9239.7 million.

What are the Application segmentation covered in the Circulating Tumor Cell Diagnostics - Market report?

Ans: The Applications covered in the Circulating Tumor Cell Diagnostics - Market report are Tumorigenesis research, EMT biomarkers development, Cancer stem cell research, Others

What are the Type segmentation covered in the Circulating Tumor Cell Diagnostics - Market report?

Ans: The Types covered in the Circulating Tumor Cell Diagnostics - Market report are CTC Enrichment, CTC Detection, CTC Analysis

1 Market Overview of Circulating Tumor Cell Diagnostics
1.1 Circulating Tumor Cell Diagnostics Market Overview
1.1.1 Circulating Tumor Cell Diagnostics Product Scope
1.1.2 Circulating Tumor Cell Diagnostics Market Status and Outlook
1.2 Global Circulating Tumor Cell Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Circulating Tumor Cell Diagnostics Market Size by Region (2018-2029)
1.4 Global Circulating Tumor Cell Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Circulating Tumor Cell Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.1 North America Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.2 Europe Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.4 Latin America Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size (2018-2029)
2 Circulating Tumor Cell Diagnostics Market by Type
2.1 Introduction
2.1.1 CTC Enrichment
2.1.2 CTC Detection
2.1.3 CTC Analysis
2.2 Global Circulating Tumor Cell Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
3 Circulating Tumor Cell Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Tumorigenesis research
3.1.2 EMT biomarkers development
3.1.3 Cancer stem cell research
3.1.4 Others
3.2 Global Circulating Tumor Cell Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
4 Circulating Tumor Cell Diagnostics Competition Analysis by Players
4.1 Global Circulating Tumor Cell Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2022)
4.3 Date of Key Players Enter into Circulating Tumor Cell Diagnostics Market
4.4 Global Top Players Circulating Tumor Cell Diagnostics Headquarters and Area Served
4.5 Key Players Circulating Tumor Cell Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Circulating Tumor Cell Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Janssen Diagnostics
5.1.1 Janssen Diagnostics Profile
5.1.2 Janssen Diagnostics Main Business
5.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.1.4 Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Janssen Diagnostics Recent Developments
5.2 Advanced Cell Diagnostics
5.2.1 Advanced Cell Diagnostics Profile
5.2.2 Advanced Cell Diagnostics Main Business
5.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.2.4 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 Advanced Cell Diagnostics Recent Developments
5.3 Aviva Biosciences
5.3.1 Aviva Biosciences Profile
5.3.2 Aviva Biosciences Main Business
5.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.3.4 Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Biocept Inc Recent Developments
5.4 Biocept Inc
5.4.1 Biocept Inc Profile
5.4.2 Biocept Inc Main Business
5.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.4.4 Biocept Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Biocept Inc Recent Developments
5.5 Biofluidica Inc.
5.5.1 Biofluidica Inc. Profile
5.5.2 Biofluidica Inc. Main Business
5.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.5.4 Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Biofluidica Inc. Recent Developments
5.6 CellTraffix Inc.
5.6.1 CellTraffix Inc. Profile
5.6.2 CellTraffix Inc. Main Business
5.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.6.4 CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 CellTraffix Inc. Recent Developments
5.7 Clearbridge BioMedics Pte Ltd
5.7.1 Clearbridge BioMedics Pte Ltd Profile
5.7.2 Clearbridge BioMedics Pte Ltd Main Business
5.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.7.4 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 Clearbridge BioMedics Pte Ltd Recent Developments
5.8 Epic Sciences Inc.
5.8.1 Epic Sciences Inc. Profile
5.8.2 Epic Sciences Inc. Main Business
5.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.8.4 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 Epic Sciences Inc. Recent Developments
5.9 Fluxion Biosciences Inc.
5.9.1 Fluxion Biosciences Inc. Profile
5.9.2 Fluxion Biosciences Inc. Main Business
5.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.9.4 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 Fluxion Biosciences Inc. Recent Developments
5.10 ScreenCell
5.10.1 ScreenCell Profile
5.10.2 ScreenCell Main Business
5.10.3 ScreenCell Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.10.4 ScreenCell Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 ScreenCell Recent Developments
5.11 Silicon Biosystems
5.11.1 Silicon Biosystems Profile
5.11.2 Silicon Biosystems Main Business
5.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.11.4 Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.11.5 Silicon Biosystems Recent Developments
5.12 Sysmex Corporation
5.12.1 Sysmex Corporation Profile
5.12.2 Sysmex Corporation Main Business
5.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.12.4 Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.12.5 Sysmex Corporation Recent Developments
5.13 Greiner Bio-One GmbH
5.13.1 Greiner Bio-One GmbH Profile
5.13.2 Greiner Bio-One GmbH Main Business
5.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.13.4 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.13.5 Greiner Bio-One GmbH Recent Developments
5.14 AdnaGen AG
5.14.1 AdnaGen AG Profile
5.14.2 AdnaGen AG Main Business
5.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.14.4 AdnaGen AG Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.14.5 AdnaGen AG Recent Developments
5.15 Apocell Inc
5.15.1 Apocell Inc Profile
5.15.2 Apocell Inc Main Business
5.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.15.4 Apocell Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.15.5 Apocell Inc Recent Developments
5.16 Biocep Ltd
5.16.1 Biocep Ltd Profile
5.16.2 Biocep Ltd Main Business
5.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.16.4 Biocep Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.16.5 Biocep Ltd Recent Developments
5.17 Canopus Bioscience Ltd
5.17.1 Canopus Bioscience Ltd Profile
5.17.2 Canopus Bioscience Ltd Main Business
5.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.17.4 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.17.5 Canopus Bioscience Ltd Recent Developments
5.18 Creatv Microtech Inc
5.18.1 Creatv Microtech Inc Profile
5.18.2 Creatv Microtech Inc Main Business
5.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.18.4 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.18.5 Creatv Microtech Inc Recent Developments
5.19 Ikonisys Inc
5.19.1 Ikonisys Inc Profile
5.19.2 Ikonisys Inc Main Business
5.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.19.4 Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.19.5 Ikonisys Inc Recent Developments
5.20 IV Diagnostics Inc
5.20.1 IV Diagnostics Inc Profile
5.20.2 IV Diagnostics Inc Main Business
5.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.20.4 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.20.5 IV Diagnostics Inc Recent Developments
5.21 Miltenyi Biotech GmbH
5.21.1 Miltenyi Biotech GmbH Profile
5.21.2 Miltenyi Biotech GmbH Main Business
5.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.21.4 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.21.5 Miltenyi Biotech GmbH Recent Developments
5.22 Nanostring Technologies Inc
5.22.1 Nanostring Technologies Inc Profile
5.22.2 Nanostring Technologies Inc Main Business
5.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.22.4 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.22.5 Nanostring Technologies Inc Recent Developments
5.23 Rarecells Diagnostics.
5.23.1 Rarecells Diagnostics. Profile
5.23.2 Rarecells Diagnostics. Main Business
5.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.23.4 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.23.5 Rarecells Diagnostics. Recent Developments
5.24 Vitatex Inc
5.24.1 Vitatex Inc Profile
5.24.2 Vitatex Inc Main Business
5.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.24.4 Vitatex Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.24.5 Vitatex Inc Recent Developments
6 North America
6.1 North America Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Circulating Tumor Cell Diagnostics Market Dynamics
11.1 Circulating Tumor Cell Diagnostics Industry Trends
11.2 Circulating Tumor Cell Diagnostics Market Drivers
11.3 Circulating Tumor Cell Diagnostics Market Challenges
11.4 Circulating Tumor Cell Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
List of Tables
    Table 1. Global Market Circulating Tumor Cell Diagnostics Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
    Table 2. Global Circulating Tumor Cell Diagnostics Market Size by Region (2018-2023) & (US$ Million)
    Table 3. Global Circulating Tumor Cell Diagnostics Market Size Share by Region (2018-2023)
    Table 4. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 5. Global Circulating Tumor Cell Diagnostics Forecasted Market Size Share by Region (2024-2029)
    Table 6. Global Circulating Tumor Cell Diagnostics Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
    Table 7. Global Circulating Tumor Cell Diagnostics Market Size by Type (2018-2023) & (US$ Million)
    Table 8. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2018-2023)
    Table 9. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 10. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2024-2029)
    Table 11. North America Circulating Tumor Cell Diagnostics Revenue by Type (2018-2023) & (US$ Million)
    Table 12. North America Circulating Tumor Cell Diagnostics Revenue by Type (2024-2029) & (US$ Million)
    Table 13. Europe Circulating Tumor Cell Diagnostics Revenue by Type (2018-2023) & (US$ Million)
    Table 14. Europe Circulating Tumor Cell Diagnostics Revenue by Type (2024-2029) & (US$ Million)
    Table 15. Asia-Pacific Circulating Tumor Cell Diagnostics Revenue by Type (2018-2023) & (US$ Million)
    Table 16. Asia-Pacific Circulating Tumor Cell Diagnostics Revenue by Type (2024-2029) & (US$ Million)
    Table 17. Latin America Circulating Tumor Cell Diagnostics Revenue by Type (2018-2023) & (US$ Million)
    Table 18. Latin America Circulating Tumor Cell Diagnostics Revenue by Type (2024-2029) & (US$ Million)
    Table 19. Middle East and Africa Circulating Tumor Cell Diagnostics Revenue by Type (2018-2023) & (US$ Million)
    Table 20. Middle East and Africa Circulating Tumor Cell Diagnostics Revenue by Type (2024-2029) & (US$ Million)
    Table 21. Global Circulating Tumor Cell Diagnostics Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
    Table 22. Global Circulating Tumor Cell Diagnostics Market Size by Application (2018-2023) & (US$ Million)
    Table 23. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2018-2023)
    Table 24. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 25. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2024-2029)
    Table 26. North America Circulating Tumor Cell Diagnostics Revenue by Application (2018-2023) & (US$ Million)
    Table 27. North America Circulating Tumor Cell Diagnostics Revenue by Application (2024-2029) & (US$ Million)
    Table 28. Europe Circulating Tumor Cell Diagnostics Revenue by Application (2018-2023) & (US$ Million)
    Table 29. Europe Circulating Tumor Cell Diagnostics Revenue by Application (2024-2029) & (US$ Million)
    Table 30. Asia-Pacific Circulating Tumor Cell Diagnostics Revenue by Application (2018-2023) & (US$ Million)
    Table 31. Asia-Pacific Circulating Tumor Cell Diagnostics Revenue by Application (2024-2029) & (US$ Million)
    Table 32. Latin America Circulating Tumor Cell Diagnostics Revenue by Application (2018-2023) & (US$ Million)
    Table 33. Latin America Circulating Tumor Cell Diagnostics Revenue by Application (2024-2029) & (US$ Million)
    Table 34. Middle East and Africa Circulating Tumor Cell Diagnostics Revenue by Application (2018-2023) & (US$ Million)
    Table 35. Middle East and Africa Circulating Tumor Cell Diagnostics Revenue by Application (2024-2029) & (US$ Million)
    Table 36. Global Circulating Tumor Cell Diagnostics Revenue (US$ Million) by Players (2018-2023)
    Table 37. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Players (2018-2023)
    Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2022)
    Table 39. Date of Key Players Enter into Circulating Tumor Cell Diagnostics Market
    Table 40. Global Circulating Tumor Cell Diagnostics Key Players Headquarters and Area Served
    Table 41. Circulating Tumor Cell Diagnostics Product Solution and Service
    Table 42. Global Circulating Tumor Cell Diagnostics Players Market Concentration Ratio (CR5 and HHI)
    Table 43. Mergers & Acquisitions, Expansion Plans
    Table 44. Janssen Diagnostics Basic Information List
    Table 45. Janssen Diagnostics Description and Business Overview
    Table 46. Janssen Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 47. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Janssen Diagnostics (2018-2023)
    Table 48. Janssen Diagnostics Recent Developments
    Table 49. Advanced Cell Diagnostics Basic Information List
    Table 50. Advanced Cell Diagnostics Description and Business Overview
    Table 51. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 52. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Advanced Cell Diagnostics (2018-2023)
    Table 53. Advanced Cell Diagnostics Recent Developments
    Table 54. Aviva Biosciences Basic Information List
    Table 55. Aviva Biosciences Description and Business Overview
    Table 56. Aviva Biosciences Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 57. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Aviva Biosciences (2018-2023)
    Table 58. Aviva Biosciences Recent Developments
    Table 59. Biocept Inc Basic Information List
    Table 60. Biocept Inc Description and Business Overview
    Table 61. Biocept Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 62. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Biocept Inc (2018-2023)
    Table 63. Biocept Inc Recent Developments
    Table 64. Biofluidica Inc. Basic Information List
    Table 65. Biofluidica Inc. Description and Business Overview
    Table 66. Biofluidica Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 67. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Biofluidica Inc. (2018-2023)
    Table 68. Biofluidica Inc. Recent Developments
    Table 69. CellTraffix Inc. Basic Information List
    Table 70. CellTraffix Inc. Description and Business Overview
    Table 71. CellTraffix Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 72. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of CellTraffix Inc. (2018-2023)
    Table 73. CellTraffix Inc. Recent Developments
    Table 74. Clearbridge BioMedics Pte Ltd Basic Information List
    Table 75. Clearbridge BioMedics Pte Ltd Description and Business Overview
    Table 76. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 77. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Clearbridge BioMedics Pte Ltd (2018-2023)
    Table 78. Clearbridge BioMedics Pte Ltd Recent Developments
    Table 79. Epic Sciences Inc. Basic Information List
    Table 80. Epic Sciences Inc. Description and Business Overview
    Table 81. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 82. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Epic Sciences Inc. (2018-2023)
    Table 83. Epic Sciences Inc. Recent Developments
    Table 84. Fluxion Biosciences Inc. Basic Information List
    Table 85. Fluxion Biosciences Inc. Description and Business Overview
    Table 86. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 87. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Fluxion Biosciences Inc. (2018-2023)
    Table 88. Fluxion Biosciences Inc. Recent Developments
    Table 89. ScreenCell Basic Information List
    Table 90. ScreenCell Description and Business Overview
    Table 91. ScreenCell Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 92. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of ScreenCell (2018-2023)
    Table 93. ScreenCell Recent Developments
    Table 94. Silicon Biosystems Basic Information List
    Table 95. Silicon Biosystems Description and Business Overview
    Table 96. Silicon Biosystems Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 97. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Silicon Biosystems (2018-2023)
    Table 98. Silicon Biosystems Recent Developments
    Table 99. Sysmex Corporation Basic Information List
    Table 100. Sysmex Corporation Description and Business Overview
    Table 101. Sysmex Corporation Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 102. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Sysmex Corporation (2018-2023)
    Table 103. Sysmex Corporation Recent Developments
    Table 104. Greiner Bio-One GmbH Basic Information List
    Table 105. Greiner Bio-One GmbH Description and Business Overview
    Table 106. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 107. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Greiner Bio-One GmbH (2018-2023)
    Table 108. Greiner Bio-One GmbH Recent Developments
    Table 109. AdnaGen AG Basic Information List
    Table 110. AdnaGen AG Description and Business Overview
    Table 111. AdnaGen AG Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 112. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of AdnaGen AG (2018-2023)
    Table 113. AdnaGen AG Recent Developments
    Table 114. Apocell Inc Basic Information List
    Table 115. Apocell Inc Description and Business Overview
    Table 116. Apocell Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 117. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Apocell Inc (2018-2023)
    Table 118. Apocell Inc Recent Developments
    Table 119. Biocep Ltd Basic Information List
    Table 120. Biocep Ltd Description and Business Overview
    Table 121. Biocep Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 122. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Biocep Ltd (2018-2023)
    Table 123. Biocep Ltd Recent Developments
    Table 124. Canopus Bioscience Ltd Basic Information List
    Table 125. Canopus Bioscience Ltd Description and Business Overview
    Table 126. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 127. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Canopus Bioscience Ltd (2018-2023)
    Table 128. Canopus Bioscience Ltd Recent Developments
    Table 129. Creatv Microtech Inc Basic Information List
    Table 130. Creatv Microtech Inc Description and Business Overview
    Table 131. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 132. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Creatv Microtech Inc (2018-2023)
    Table 133. Creatv Microtech Inc Recent Developments
    Table 134. Ikonisys Inc Basic Information List
    Table 135. Ikonisys Inc Description and Business Overview
    Table 136. Ikonisys Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 137. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Ikonisys Inc (2018-2023)
    Table 138. Ikonisys Inc Recent Developments
    Table 139. IV Diagnostics Inc Basic Information List
    Table 140. IV Diagnostics Inc Description and Business Overview
    Table 141. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 142. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of IV Diagnostics Inc (2018-2023)
    Table 143. IV Diagnostics Inc Recent Developments
    Table 144. Miltenyi Biotech GmbH Basic Information List
    Table 145. Miltenyi Biotech GmbH Description and Business Overview
    Table 146. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 147. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Miltenyi Biotech GmbH (2018-2023)
    Table 148. Miltenyi Biotech GmbH Recent Developments
    Table 149. Nanostring Technologies Inc Basic Information List
    Table 150. Nanostring Technologies Inc Description and Business Overview
    Table 151. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 152. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Nanostring Technologies Inc (2018-2023)
    Table 153. Nanostring Technologies Inc Recent Developments
    Table 154. Rarecells Diagnostics. Basic Information List
    Table 155. Rarecells Diagnostics. Description and Business Overview
    Table 156. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 157. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Rarecells Diagnostics. (2018-2023)
    Table 158. Rarecells Diagnostics. Recent Developments
    Table 159. Vitatex Inc Basic Information List
    Table 160. Vitatex Inc Description and Business Overview
    Table 161. Vitatex Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
    Table 162. Revenue (US$ Million) in Circulating Tumor Cell Diagnostics Business of Vitatex Inc (2018-2023)
    Table 163. Vitatex Inc Recent Developments
    Table 164. North America Circulating Tumor Cell Diagnostics Market Size by Country (2018-2023) & (US$ Million)
    Table 165. North America Circulating Tumor Cell Diagnostics Market Size by Country (2024-2029) & (US$ Million)
    Table 166. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2018-2023) & (US$ Million)
    Table 167. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2024-2029) & (US$ Million)
    Table 168. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 169. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2018-2023) & (US$ Million)
    Table 170. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2024-2029) & (US$ Million)
    Table 171. Asia-Pacific Circulating Tumor Cell Diagnostics Market Share by Region (2018-2023)
    Table 172. Asia-Pacific Circulating Tumor Cell Diagnostics Market Share by Region (2024-2029)
    Table 173. Latin America Circulating Tumor Cell Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 174. Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2018-2023) & (US$ Million)
    Table 175. Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2024-2029) & (US$ Million)
    Table 176. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 177. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2018-2023) & (US$ Million)
    Table 178. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2024-2029) & (US$ Million)
    Table 179. Circulating Tumor Cell Diagnostics Market Trends
    Table 180. Circulating Tumor Cell Diagnostics Market Drivers
    Table 181. Circulating Tumor Cell Diagnostics Market Challenges
    Table 182. Circulating Tumor Cell Diagnostics Market Restraints
    Table 183. Research Programs/Design for This Report
    Table 184. Key Data Information from Secondary Sources
    Table 185. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Circulating Tumor Cell Diagnostics Market Size Year-over-Year 2018-2029 & (US$ Million)
    Figure 2. Global Circulating Tumor Cell Diagnostics Market Size (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Circulating Tumor Cell Diagnostics Market Share by Regions: 2022 VS 2029
    Figure 4. Global Circulating Tumor Cell Diagnostics Forecasted Market Size Share by Region (2024-2029)
    Figure 5. North America Circulating Tumor Cell Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 6. Europe Circulating Tumor Cell Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 7. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 8. Latin America Circulating Tumor Cell Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 9. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 10. Product Picture of CTC Enrichment
    Figure 11. Global CTC Enrichment Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 12. Product Picture of CTC Detection
    Figure 13. Global CTC Detection Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 14. Product Picture of CTC Analysis
    Figure 15. Global CTC Analysis Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 16. Global Circulating Tumor Cell Diagnostics Market Size Share by Type: 2022 & 2029
    Figure 17. North America Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2018-2029)
    Figure 18. Europe Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2018-2029)
    Figure 19. Asia-Pacific Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2018-2029)
    Figure 20. Latin America Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2018-2029)
    Figure 21. Middle East and Africa Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2018-2029)
    Figure 22. Tumorigenesis research Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 23. EMT biomarkers development Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 24. Cancer stem cell research Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 25. Others Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 26. Global Circulating Tumor Cell Diagnostics Market Size Share by Application: 2022 & 2029
    Figure 27. North America Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2018-2029)
    Figure 28. Europe Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2018-2029)
    Figure 29. Asia-Pacific Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2018-2029)
    Figure 30. Latin America Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2018-2029)
    Figure 31. Middle East and Africa Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2018-2029)
    Figure 32. Circulating Tumor Cell Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 33. Global Top 5 and Top 10 Players Circulating Tumor Cell Diagnostics Market Share in 2022
    Figure 34. North America Circulating Tumor Cell Diagnostics Market Share by Country (2018-2029)
    Figure 35. U.S. Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 36. Canada Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 37. Germany Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 38. France Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 39. U.K. Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 40. Italy Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 41. Russia Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 42. Nordic Countries Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 43. Asia-Pacific Circulating Tumor Cell Diagnostics Market Share by Region (2018-2029)
    Figure 44. China Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 45. Japan Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 46. South Korea Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 47. Southeast Asia Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 48. India Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 49. Australia Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 50. Latin America Circulating Tumor Cell Diagnostics Market Share by Country (2018-2029)
    Figure 51. Mexico Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 52. Brazil Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 53. Middle East & Africa Circulating Tumor Cell Diagnostics Market Share by Country (2018-2029)
    Figure 54. Turkey Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 55. Saudi Arabia Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 56. UAE Circulating Tumor Cell Diagnostics Market Size (2018-2029) & (US$ Million)
    Figure 57. Bottom-up and Top-down Approaches for This Report
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3350

This license allows only one user to access the PDF.
Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Hurthle Cell Carcinoma Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-35B1140
Sun Feb 11 00:00:00 UTC 2024

Add to Cart

Global Oncology Based Molecular Diagnostics Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-6P7589
Thu Feb 08 00:00:00 UTC 2024

Add to Cart

Global Internal Radiation Therapy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-17G14298
Thu Feb 08 00:00:00 UTC 2024

Add to Cart

Global External beam Radiation Therapy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-5C14164
Thu Feb 08 00:00:00 UTC 2024

Add to Cart